Day 1 - Thursday, 18 November 2021

 08:00Registration and welcome coffee 
 Session 1: Hematology
Chairs: tbc

Incorporating novel targeted therapies into combination chemotherapy in acute leukemia (tbc)
Keith Pratz
Perelman School of Medicine
University of Pennsylvania, USA



Preclinical to clinical translation in leukemia (tbc)
Sharyn Baker
Ohio State University College of Pharmacy, USA

  Abstract-driven presentations 


 10:00Discussion & session evaluation 
 10:30Coffee Break 
 Session 2: Therapy optimization
Chairs: tbc
 11:00Cell lines vs. Organoids vs. Xenografts (and Organ on a chip) (tbc)
Marc van de Wetering
The Princess Máxima Center, the Netherlands
 11:30Immunotherapy and intestinal microbiota
Laurence Zitvogel
Gustave Roussy Cancer Campus, France
  Abstract-driven presentations


 12:30Discussion & session evaluation 
 Session 3: Efficient drug development of novel anticancer treatments
Chairs: tbc

Regulatory aspects on oncology dose finding strategies in an era of streamlined drug development (tbc)
Julie Bullock
Certara, USA


Early clinical trials - optimized dosing (tbc)
Jesús García-Foncillas
Hospital Jiménez-Díaz, Spain


Clinical pharmacology in oncology drug development: Enabling rational dose selection from translational to global drug development
Karthik Venkatakrishnan
                     EMD Serono, USA

  Abstract-driven presentations 
 15:30 (#05) 
 15:45 (#06) 
 16:00Discussion & session evaluation 
 16:30Poster viewing session 1 & welcome drinks 
 18:00Networking dinner (optional) 

Day 2 - Friday, 19 November 2021

 Session 4: Drug combinations and Drug interactions
Chairs: tbc

Optimizing combination cancer therapy in light of patient variability (tbc)
Peter Sorger
Harvard Medical School, USA


A novel, model based approach to combination, phase I clinical trial design: The ATRiUM trial
Duncan Jodrell
University of Cambridge, UK

  Abstract-driven presentations 
 09:45 (#08) 
 10:00Discussion & session evaluation 
 10:30Poster viewing session 2 & coffee break 
 Session 5: Pharmacometrics in Drug Development and Clinical Practice
Chairs: tbc

Physiology-Based Pharmacokinetic (PBPK) Modeling to Support Early Clinical Development in Oncology
Maud Beneton
Servier, France


How cancer disease state and drug target can influence exposure, making PK-PD analysis challenging
Matts Kågedal
Genentech, Sweden

  Abstract-driven presentations 
 12:15 (#10)

 12:30Discussion & session evaluation 
 Session 6: Biomarker for Dose Selection in The 2020's
Chairs: tbc

Biomarker development in immunotherapy
Joachim Aerts
Erasmus MC Cancer Centre, the Netherlands


Drug selection based on specific mutations in patients with lung cancer (tbc)
Joop de Langen
VU University Medical Center, the Netherlands

  Abstract-driven presentation 
 15:00 (#11) 
 15:30Discussion & session evaluation 
  Closing of the workshop by the conference chairs